参考文献/References:
[1] Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975.
[2] Shah SJ,Katz DH,Selvaraj S,et al. Phenomapping for novel classification of heart failure with preserved ejection fraction[J]. Circulation,2014,131(3):269-279.
[3] Dhingra A,Garg A,Kaur S,et al. Epidemiology of heart failure with preserved ejection fraction[J]. Curr Heart Fail Rep,2014,11(4):354 -365.
[4] Hiebert JB,Vacek J,Shah Z,et al. Use of speckle tracking to assess heart failure with preserved ejection fraction[J]. J Cardiol,2019,74(5)397-402.
[5] Chan MM,Lam CS. How do patients with heart failure with preserved ejection fraction die? [J]. Eur J Heart Fail,2013,15:604-613.
[6] Sanders-van Wijk S,van Empel V,Davarzani N,et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction[J]. Eur J Heart Fail,2015,17(10):1006-1014.
[7] Paulus WJ,Tsch?pe C. A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J].
[8] Iacobellis G,Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ[J]. Horm Metab Res,2008,40(7):442-445.
[9] Bernardo ME,Fibbe WE. Mesenchymal stromal cells:sensors and switchers of inflammation[J]. Cell Stem Cell,2013,13(4):392-402.
[10] Naftali-Shani N,Levin-Kotler LP,Palevski D,et al. Left ventricular dysfunction switches mesenchymal stromal cells toward an inflammatory phenotype and impairs their reparative properties via toll-like receptor-4[J]. Circulation,2017,135(23):2271-2287.
[11] Shah SJ,Lam CSP,Svedlund S,et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction:PROMIS-HFpEF[J]. Eur Heart J,2018,39(37):3439-3450.
[12] Loudon BL,Noordali H,Gollop ND,et al. Present and future pharmacotherapeutic agents in heart failure:an evolving paradigm[J]. Br J Pharmacol,2016,173(12):1911-1924.
[13] Witteles RM,Fowler MB. Insulin-resistant cardiomyopathy clinical evidence,mechanisms,and treatment options[J]. J Am Coll Cardiol,2008,51(2):93-102.
[14] van Tassell BW,Raleigh JM,Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease[J]. Curr Heart Fail Rep,2015,12(1):33-41.
[15] Redfield MM,Anstrom KJ,Levine JA,et al. Isosorbide mononitrate in heart failure with preserved ejection fraction[J]. N Engl J Med,2015,373(24):2314-2324.
[16] Borlaug BA,Anstrom KJ,Lewis GD,et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction:the INDIE-HFpEF randomized clinical trial[J]. JAMA,2018,320(17):1764-1773.
[17] Pieske B,Patel MJ,Westerhout CM,et al. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial[J]. Eur J Heart Fail,2019,21(12):1596-1604.
[18] Solomon SD,Vaduganathan M,Claggett BL,et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure[J]. Circulation,2019,141(5):352-361.
[19] Cowie MR,Fisher M.?SGLT2 inhibitors:mechanisms of cardiovascular benefit beyond glycaemic control[J]. Nat Rev Cardiol,2020,17(12):761-772.
[20] Lima-Martínez MM,Paoli M,Rodney M,et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity:a pilot study[J]. Endocrine,2016,51(3):448-455.
[21] Cameron AR,Morrison VL,Levin D,et al. Anti-inflammatory effects of metformin irrespective e of diabetes status[J]. Circ Res,2016,119(5):652-665.
[22] Lee MS,Duan L,Clare R,et al. Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction[J].
[23] Zannad F,McMurray JJ,Krum H,et al. Eplerenone in patients with systolic heart failure and mild symptoms[J]. N Engl J Med,2011,364(1):11-21.
[24] Pitt B,Pfeffer MA,Assmann SF,et al. Spironolactone for heart failure with preserved ejection fraction[J]. N Engl J Med,2014,370(15):1383-1392.
[25] Zhou X,Chen JC.?Is treatment with trimetazidine beneficial in patients with chronic heart failure? [J]. PLoS One,2014,9(5): e94660.
[26] Grajek S,Michalak M. The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure[J]. Cardiology ,2015,131(1):22-29.
[27] Steggall A,Mordi IR,Lang CC. Targeting metabolic modulation and mitochondrial dysfunction in the treatment of heart failure[J]. Diseases,2017,5(2):14.
[28] Maier LS,Layug B,Karwatowska-Prokopczuk E,et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction:the RALI-DHF proof-of-concept study[J]. JACC Heart Fail,2013,1(2):115-122.
相似文献/References:
[1]孙慧雪 郑美芳 李海 孙磊 顾翔.远程医疗应用于射血分数保留性心力衰竭的现状及进展[J].心血管病学进展,2020,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
SUN Huixue,ZHENG Meifang,LI Hai,et al.Status Progress of Telemedicine in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(3):251.[doi:10.16806/j.cnki.issn.1004-3934.20.03.009]
[2]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(3):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[3]高可 杨蕾 姚新叶 郑小璞.射血分数保留性心力衰竭动物模型的研究进展[J].心血管病学进展,2020,(8):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
GAO Ke,YANG Lei,YAO Xinye,et al.Advances in Animal Models ofHeart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2020,(3):834.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.013]
[4]韩雅洁 范小倩 巩彩霞 赵子龙 乔成栋.致心律失常性左室心肌病的研究进展[J].心血管病学进展,2021,(4):342.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.013]
HAN Yajie,FAN Xiaoqian,GONG Caixia,et al.Arrhythmogenic Left Ventricular Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(3):342.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.013]
[5]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(3):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[6]刘春秋 熊双 刘剑刚 董国菊.射血分数保留性心力衰竭的诊断的研究进展[J].心血管病学进展,2021,(9):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
LIU Chunqiu,XIONG Shuang,LIU Jiangang,et al.Diagnosis of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2021,(3):784.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[7]宋雨 李耘 马丽娜.老年人衰弱和射血分数保留性心力衰竭病理生理学机制的研究进展[J].心血管病学进展,2022,(1):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
SONG Yu,LI Yun,MA Lina.Pathophysiological Mechanisms of Frailty and Heart Failure with Preserved Ejection Fraction in the Elderly[J].Advances in Cardiovascular Diseases,2022,(3):38.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.010]
[8]赵菲 刘永铭.抗炎类药物对射血分数保留性心力衰竭患者心外膜脂肪组织的影响[J].心血管病学进展,2022,(1):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
ZHAO Fei,LIU Yongming.Effects of Anti-Inflammatory Drugs on Epicardial Adipose Tissue in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(3):41.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.011]
[9]张文珺 牛小伟 刘永铭.m6A甲基化在射血分数保留性心力衰竭中的作用的研究进展[J].心血管病学进展,2022,(1):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
ZHANG Wenjun,NIU Xiaowei,LIU Yongming.m6A RNA Methylation in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(3):44.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.012]
[10]卢甜甜 张轶.射血分数保留性心力衰竭左心室心肌力学变化及评估的研究进展[J].心血管病学进展,2022,(4):331.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.011]
LU Tiantian,ZHANG Yi?/html>.Changes and Evaluation of Left Ventricular Myocardial Mechanical?n Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(3):331.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.011]